Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 173, Issue 12, 2006, Pages 1348-1355

  Koeman, Mirelle ^a   Van Der Ven, Andre J A M ^b   Hak, Eelko ^b   Joore, Hans C A ^b   Kaasjager, Karin ^b   De Smet, Annemarie G A ^b   Ramsay, Graham ^b   Dormans, Tom P J ^b   Aarts, Leon P H J ^b   De Bel, Ernst E ^b   Hustinx, Willem N M ^b   Van Der Tweel, Ingeborg ^b   Hoepelman, Andy M ^b   Bonten, Marc J M ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

Chlorhexidine; Prevention; Ventilator associated pneumonia

Indexed keywords

CHLORHEXIDINE; COLISTIN; PLACEBO;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; ORAL BIOPSY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; VENTILATOR ASSOCIATED PNEUMONIA;

ADMINISTRATION, TOPICAL; ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; CHLORHEXIDINE; COLISTIN; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INTENSIVE CARE; LENGTH OF STAY; MALE; MIDDLE AGED; MOUTH; OROPHARYNX; PLACEBOS; PNEUMONIA, BACTERIAL; TIME FACTORS; TRACHEA; VENTILATORS, MECHANICAL;

EID: 33745132106     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200505-820OC     Document Type: Article

References (51)

1. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999;27:887-892.
2. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study. EPIC International Advisory Committee. JAMA 1995;274:639-644.
3. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903.
4. Bergmans DCJJ, Bonten MJM, Gaillard CA, van Tiel FH, van der Geest S, de Leeuw PW, Stobberingh EE. Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother 1997;39:527-535.
5. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999;159:1249-1256.
6. Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox MJ, Cohen MM, Fraser VJ. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003;31:1312-1317.
7. van Nieuwenhoven CA, Buskens E, Bergmans DC, van Tiel FH, Ramsay G, Bonten MJ. Oral decontamination is cost-saving in the prevention of ventilator-associated pneumonia in intensive care units. Crit Care Med 2004;32:126-130.
8. Johanson WG Jr, Pierce AK, Sanford JP, Thomas GD. Nosocomial respiratory infections with Gram-negative bacilli: the significance of colonization of the respiratory tract. Ann Intern Med 1972;77:701-706.
9. Johanson WG Jr, Pierce AK, Sanford JP. Changing pharyngeal bacterial flora of hospitalized patients: emergence of gram-negative bacilli. N Engl J Med 1969;281:1137-1140.
10. Bonten MJM, Gaillard CA, de Leeuw PW, Stobberingh EE. Role of colonization of the upper intestinal tract in the pathogenesis of ventilator-associated pneumonia. Clin Infect Dis 1997;24:309-319.
11. Pugin J, Auckenthaler R, Lew DP, Suter PM. Oropharyngeal decontamination decreases incidence of ventilator-associated pneumonia: a randomized, placebo-controlled, double-blind clinical trial. JAMA 1991;265:2704-2710.
12. Bergmans DC, Bonten MJ, Gaillard CA, Paling JC, van der Geest S, van Tiel FH, Beysens AJ, de Leeuw PW, Stobberingh EE. Prevention of ventilator- associated pneumonia by oral decontamination: a prospective, randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2001;164:382-388.
13. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004;53:1-36.
14. Emilson CG. Susceptibility of various microorganisms to chlorhexidine. Scand J Dent Res 1977;85:255-265.
15. Hammond SA, Morgan JR, Russell AD. Comparative susceptibility of hospital isolates of gram-negative bacteria to antiseptics and disinfectants. J Hosp Infect 1987;9:255-264.
16. Katz SL, Ho SL, Coates AL. Nebulizer choice for inhaled colistin treatment in cystic fibrosis. Chest 2001;119:250-255.
17. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-838.
18. Catchpole CR, Andrews JM, Brenwald N, Wise R. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997;39:255-260.
19. DeRiso AJ, Ladowski JS, Dillon TA, Justice JW, Peterson AC. Chlorhexidne gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. Chest 1996;109:1556-1561.
20. Bergmans DCJJ, Bonten MJM, de Leeuw PW, Stobberingh EE. Reproducibility of quantitative cultures of endotracheal aspirates from mechanically ventilated patients. J Clin Microbiol 1997;35:796-798.
21. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829.
22. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991;143:1121-1129.
23. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982;1:121-129.
24. Whitehead J. The design and analysis of sequential clinical trials, rev. 2nd ed. Chinchester, UK: John Wiley & Son; 1997.
25. MPS Research Unit. PEST 4: operating manual. Reading, UK: The University of Reading; 2000.
26. Bonten MJM, Bergmans DCJJ, Ambergen AW, de Leeuw PW, van der Geest S, Stobberingh EE, Gaillard CA. Risk factors for pneumonia, and colonization of respiratory tract and stomach in mechanically ventilated ICU patients. Am J Respir Crit Care Med 1996;154:1339-1346.
27. Garrouste-Org M, Chevret S, Arlet G, Marie O, Rouveau M, Popoff N, Schlemmer B. Oropharyngeal or gastric colonization and nosocomial pneumonia in adult intensive care unit patients: a prospective study based on genomic DNA analysis. Am J Respir Crit Care Med 1997;156:1647-1655.
28. Violán JS, Fernández JA, Bordes-Benítez A, Cardenosa-Cendrero JA, de Castro FR. Impact of quantitative invasive diagnostic techniques in the management and outcome of mechancally ventilated patients with suspected pneumonia. Crit Care Med 2000;28:2737-2741.
29. Russell AD, Day MJ. Antibacterial activity of chlorhexidine. J Hosp Infect 1993;25:229-238.
30. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003;37:e154-e160.
31. Stein A, Raoult D. Colistin: an antimicrobial for the 21st century? Clin Infect Dis 2002;35:901-902.
32. Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-1011.
33. Cook DJ, Walter SD, Cook RJ, Griffith LE, Guyatt G, Leasa D, Jaeschke RZ, Brun-Buisson C. Incidence and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998;129:433-440.
34. Houston S, Hougland P, Anderson JJ, LaRocco M, Kennedy V, Gentry LO. Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery. Am J Crit Care 2002;11:567-570.
35. Fourrier F, Dubois D, Pronnier P, Herbecq P, Leroy O, Desmettre T, Pottier-Cau E, Boutigny H, Di Pompeo C, Durocher A, et al.; PIRAD Study Group. Effect of gingival and dental plaque antiseptic decontamination on nosocomial infections acquired in the intensive care unit: a double-blind placebo-controlled multicenter study. Crit Care Med 2005;33:1728-1735.
36. Collard HR, Saint S, Matthay MA. Prevention of ventilator-associated pneumonia: an evidence-based systematic review. Ann Intern Med 2003;138:494-501.
37. Dodek P, Keenan SP, Cook D, Heyland DK, Jacka MJ, Hand L, Muscedere J, Foster D, Mehta N, Hall R, et al. Evidence-based clinical practice guideline for the prevention of ventilator-associated pneumonia. Ann Intern Med 2004;141:303-313.
38. van Nieuwenhoven CA, Buskens E, van Tiel FH, Bonten MJM. Relationship between methodological trial quality and the effects of selective digestive decontamination on pneumonia and mortality in critically ill patients. JAMA 2001;286:335-340.
39. de Jonge E, Schultz MJ, Spanjaard L, Bossuyt PM, Vroom MB, Dankert J, Kesecioglu J. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003;362:1011-1016.
40. Verbrugh A. Selective decontamination of digestive tract in intensive care. Lancet 2003;362:2117-2118.
41. Kim SW, Kami M, Kobayashi K, Takaue Y, Honda O. Selective decontamination of digestive tract in intensive care. Lancet 2003;362:2118-2120.
42. Bonten MJ, Kluytmans J, de Smet AM, Bootsma M, Hoes A. Selective decontamination of digestive tract in intensive care. Lancet 2003;362:2118-2119.
43. Pingleton SK, Fagon JY, Leeper KV. Patient selection for clinical investigation of ventilator-associated pneumonia: criteria for evaluating diagnostic techniques. Chest 1992;102:553S-556S.
44. Gastinne H, Wolff M, Lachatre G, Boiteau P, Savy FP. Antibiotic levels in bronchialtree and serum during selective digestive decontamination. Intensive Care Med 1991;17:215-218.
45. Fagon JY, Chastre J, Vaugnat A, Trouillet JL, Novara A, Gibert C. Nosocomial pneumonia and mortality among patients in intensive care units. JAMA 1996;275:866-869.
46. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributal mortality and hospital stay. Am J Med 1993;94:281-288.
47. Bregeon F, Papazian L, Visconti A, Gregoire R, Thirion X, Gouin F. Relationship of microbiologic diagnostic criteria to morbidity and mortality in patients with ventilator-associated pneumonia. JAMA 1997;277:655-662.
48. Papazian L, Bregeon F, Thirion X, Gregoire R, Saux P, Denis JP, Perin G, Charrel J, Dumon JF, Affray JP, et al. Effect of ventilator-associated pneumonia on mortality and morbidity. Am J Respir Crit Care Med 1996;154:91-97.
49. Bonten MJM, Froon AHM, Gaillard CA, Greve JWM, de Leeuw PW, Drent M, Stobberingh EE, Buurman WA. The systemic inflammatory respons in the development of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156:1105-1113.
50. Kollef MH, Ward S. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31:S131-S138.
51. Wilcox MH, Hall J, Gill AB, Fawley WN, Parnell P, Verity P. Effectiveness of topical chlorhexidine powder as an alternative to hexachlorophane for the control of Staphylococcus aureus in neonates. J Hosp Infect 2004;56:156-159.